Optimizing Cataract Surgery: Surgeon Controlled Dropless Solutions
Dr Donnenfeld, Dr Singh, Dr Houser, Dr Yeu
Cataract Surgery Pearls from Forward Thinking Ophthalmologists
Dr Donnenfeld, Dr Singh, Dr Houser, Dr Yeu
Transforming Ophthalmology Practices with Dropless Solutions
Dr Donnenfeld, Dr Singh, Dr Houser, Dr Yeu
A Dropless Solution for the Forward-Thinking Ophthalmologist
Dr Donnenfeld, Dr Singh, Dr Houser, Dr Yeu
Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and...
Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract...
Dr. Wilson shares his study results demonstrating that OMIDRIA is safe for use in...
Dr. Visco discusses the surgical and patient benefits of continuous intracameral administration of OMIDRIA.
This retrospective study shows that patients receiving OMIDRIA and topical NSAID without postoperative topical...
This retrospective study demonstrated a reduction in the quantity of opioids prescribed for patients...
This prospective study demonstrated that patients treated with OMIDRIA had a statistically significant lower...
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.